222 related articles for article (PubMed ID: 32085669)
1. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669
[TBL] [Abstract][Full Text] [Related]
2. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG
Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109
[TBL] [Abstract][Full Text] [Related]
3. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
Pizzamiglio S; Cosentino G; Ciniselli CM; De Cecco L; Cataldo A; Plantamura I; Triulzi T; El-Abed S; Wang Y; Bajji M; Nuciforo P; Huober J; Ellard SL; Rimm DL; Gombos A; Daidone MG; Verderio P; Tagliabue E; Di Cosimo S; Iorio MV
Cancer Med; 2022 Jan; 11(2):332-339. PubMed ID: 34921525
[TBL] [Abstract][Full Text] [Related]
4. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
[TBL] [Abstract][Full Text] [Related]
7. Plasma-based microRNA signatures in early diagnosis of breast cancer.
Li X; Zou W; Wang Y; Liao Z; Li L; Zhai Y; Zhang L; Gu S; Zhao X
Mol Genet Genomic Med; 2020 May; 8(5):e1092. PubMed ID: 32124558
[TBL] [Abstract][Full Text] [Related]
8. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.
Rezaei Z; Dastjerdi K; Allahyari A; ShahidSales S; Talebian S; Maharati A; Zangooie A; Zangouei AS; Sadri F; Sargazi S
Toxicol Appl Pharmacol; 2023 Sep; 475():116652. PubMed ID: 37557922
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients.
Lote H; Mousoullou F; Vlachogiannis G; Lampis A; Satchwell L; Peckitt C; Fong C; Begum R; Kidd S; Cromarty S; Gordon A; Fribbens C; Rao S; Starling N; Chau I; Cunningham D; Valeri N
Front Oncol; 2023; 13():1258365. PubMed ID: 38094609
[TBL] [Abstract][Full Text] [Related]
11. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
[TBL] [Abstract][Full Text] [Related]
12. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
Di Cosimo S; Ciniselli CM; Pizzamiglio S; Cappelletti V; Silvestri M; El-Abed S; Izquierdo M; Bajji M; Nuciforo P; Huober J; Cameron D; Chia S; Gomez HL; Iorio MV; Vingiani A; Pruneri G; Verderio P
Front Oncol; 2022; 12():1028825. PubMed ID: 36798690
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Serum MicroRNAs (miR-9-5p, miR-17-5p, and miR-148a-3p) as Potential Biomarkers of Breast Cancer.
Li X; Tang X; Li K; Lu L
Biomed Res Int; 2022; 2022():9961412. PubMed ID: 35111850
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.
Normann LS; Aure MR; Leivonen SK; Haugen MH; Hongisto V; Kristensen VN; Mælandsmo GM; Sahlberg KK
Sci Rep; 2021 May; 11(1):10893. PubMed ID: 34035375
[TBL] [Abstract][Full Text] [Related]
15. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Powles RL; Redmond D; Sotiriou C; Loi S; Fumagalli D; Nuciforo P; Harbeck N; de Azambuja E; Sarp S; Di Cosimo S; Huober J; Baselga J; Piccart-Gebhart M; Elemento O; Pusztai L; Hatzis C
JAMA Oncol; 2018 Nov; 4(11):e181564. PubMed ID: 29902299
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity.
Yadi W; Shurui C; Tong Z; Suxian C; Qing T; Dongning H
BMC Cardiovasc Disord; 2020 Feb; 20(1):43. PubMed ID: 32013934
[TBL] [Abstract][Full Text] [Related]
17. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.
Zhang J; Raju GS; Chang DW; Lin SH; Chen Z; Wu X
Cancer; 2018 Feb; 124(4):785-796. PubMed ID: 29112225
[TBL] [Abstract][Full Text] [Related]
18. Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer.
Zhang J; Zhang Y; Shen W; Fu R; Ding Z; Zhen Y; Wan Y
Biomed Pharmacother; 2019 Sep; 117():109058. PubMed ID: 31176168
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
[TBL] [Abstract][Full Text] [Related]
20. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
Di Cosimo S; Triulzi T; Pizzamiglio S; De Cecco L; de Azambuja E; Fumagalli D; Putzai L; Harbeck N; Izquierdo M; Peña L; Daidone MG; Huober J; Gori S; Cinieri S; Torri V; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Tagliabue E
Eur J Cancer; 2019 Sep; 118():1-9. PubMed ID: 31284184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]